Prehospital 1-Hour Sepsis Bundle Fails to Cut Mortality

This cluster-randomized French trial tested whether initiating a complete sepsis resuscitation bundle in the ambulance improves survival, a question directly relevant to how ICU and EMS pharmacists prioritize early antibiotics, fluids, and vasopressors.

📅 Journal publication: Aug 10, 2026 · Last updated: Oct 7, 2026

★ Editor's Pickseptic shocksepsisprehospitalresuscitation bundlenorepinephrineceftriaxonepiperacillin-tazobactamhydrocortisonecrystalloidscluster-randomized trialmortalitySurviving Sepsis Campaignemergency medicinecritical care Critical Care / ICU

Also in Emergency Medicine / Toxicology

Background Information

Prehospital 1-hour septic shock bundle shows no mortality advantage.

Septic shock requires timely intervention, and this study explores whether a 1-hour resuscitation bundle in a prehospital setting can improve outcomes. The study found no significant reduction in 28-day mortality with the 1-hour resuscitation bundle compared to usual care (22% vs 27%, risk ratio 0.81; p = 0.16). Despite the intervention, the results did not show a mortality benefit, possibly due to enrollment imbalances and minimal differences between groups. Caution is advised in interpreting these results. A 1-hour resuscitation bundle in prehospital care did not significantly reduce mortality in septic shock.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Jouffroy R, Annane D, Elie C, Mira JP, Jilet L, Gueye P, Vivien B, and the Service d’Aide Médicale Urgente (SAMU) Save Sepsis study group

Citation: Jouffroy R, Annane D, Elie C, et al. A 1-Hour Resuscitation Bundle for Prehospital Management of Septic Shock. Critical care medicine. 2026. doi:10.1097/CCM.0000000000007283

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →